Hereditary Testing Market Study Explores Industry Growth Toward $10.17 Billion

The hereditary testing market is positioned for notable expansion as advancements in genomics and personalized medicine continue to gain momentum. Increasing integration of genetic insights into healthcare, along with technological innovations, are playing key roles in shaping this evolving industry. Here's an overview of the market's expected growth, leading companies, prominent trends, and crucial segments defining the hereditary testing landscape.

Projected Growth and Market Size of the Hereditary Testing Market
Forecasts suggest that the hereditary testing market will reach $10.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.9%. This robust expansion is driven by multiple factors such as the broader incorporation of genomics into everyday medical care, heightened demand for precision medicine, and the scaling up of population-wide genetic screening initiatives. Additionally, increased utilization of digital platforms for genetic data and a stronger emphasis on preventive healthcare genomics are contributing to this upward trajectory. Key developments anticipated during this period include wider adoption of next-generation sequencing tests, growing interest in predictive and carrier genetic testing, enhanced AI-based variant interpretation, expanded prenatal and newborn screening programs, and more personalized genetic counseling services.

The hereditary testing market size has grown strongly in recent years. It will grow from $6.62 billion in 2025 to $7.23 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to advancements in genetic sequencing technologies, increasing awareness of inherited disorders, expansion of clinical genetics programs, declining cost of genetic testing, growth of diagnostic laboratory networks.

Download a free sample of the hereditary testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25782&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Major Industry Players Influencing the Hereditary Testing Market
A range of influential organizations shapes the hereditary testing market, including established names like F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, and Quest Diagnostics Incorporated. Other significant participants are Agilent Technologies Inc., Illumina Inc., CooperSurgical Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Invitae Corporation, GeneDx LLC, Twist Bioscience Corporation, Color Health Inc., MedGenome Inc., SOPHiA GENETICS SA, Gene By Gene Ltd., Dante Labs Inc., and 23mofang Co. Ltd.

A notable recent development in the market occurred in May 2025, when GeneDx LLC, a US-based genetic testing biotechnology firm, acquired Fabric Genomics. Though the financial terms were undisclosed, this acquisition aims to boost GeneDx's genomic interpretation capabilities by leveraging Fabric Genomics' AI-powered platform. This move is expected to enhance hereditary disease diagnostics with faster and more scalable genetic analysis solutions, further strengthening GeneDx's market position.

View the full hereditary testing market report:
https://www.thebusinessresearchcompany.com/report/hereditary-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends and Technological Advances in Hereditary Testing
Leading hereditary testing companies are prioritizing innovations in genetic test kits to improve diagnostic accuracy, reduce turnaround times, and identify a wider array of genetic mutations. Genetic test kits are specialized diagnostic tools that analyze an individual's DNA to pinpoint mutations or variations linked to inherited disorders or disease risks. For example, in July 2023, Devyser Diagnostics AB, a Sweden-based biotech company specializing in DNA diagnostic kits, launched two new targeted next-generation sequencing kits: Devyser LynchFAP and Devyser BRCA PALB2.

The Devyser LynchFAP kit stands out by providing comprehensive analysis of the PMS2 gene, overcoming challenges posed by its closely related pseudogene PMS2CL, alongside nine other critical genes tied to hereditary colorectal cancer syndromes. Meanwhile, Devyser BRCA PALB2 offers a streamlined, single-tube testing solution for detecting mutations in BRCA1, BRCA2, and PALB2 genes across both blood and tumor samples. These kits are designed to support efficient lab workflows and include specialized software that facilitates accurate detection of hereditary cancer risks.

Dominant Segments Within the Hereditary Testing Market
The hereditary testing market is categorized into several important segments, including:

1) Test Types: Predictive Testing, Carrier Testing, Prenatal Testing, Newborn Screening, Diagnostic Testing, and Other Test Types
2) Sample Types: Blood Samples, Saliva Samples, Tissue Samples, Buccal Swabs, Amniotic Fluid, and Cord Blood Samples
3) Technologies Used: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Sanger Sequencing, Microarray Technology, and Whole Genome Sequencing (WGS)
4) Applications: Oncology, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders, and Other Uses
5) End Users: Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, and Patients/Consumers

In addition, the predictive testing segment is further broken down into tests for mutations in BRCA1 and BRCA2 genes, Lynch Syndrome, Familial Hypercholesterolemia, Huntington's Disease, and Cardiomyopathy. Carrier testing includes screenings for Cystic Fibrosis, Tay-Sachs, Spinal Muscular Atrophy (SMA), Thalassemia, and Sickle Cell. Prenatal testing covers Non-Invasive Prenatal Testing (NIPT), Chorionic Villus Sampling (CVS), Amniocentesis, Expanded Carrier Screening in prenatal contexts, and Cell-Free Fetal DNA testing. Newborn screening ranges from ket*onuria (PKU) and Congenital Hypothyroidism to Cystic Fibrosis, Sickle Cell Disease, hearing loss panels, and metabolic disorder panels. Diagnostic testing includes rare disease genetics, inherited cancer diagnostics, cardiogenetic panels, neurogenetic disorder testing, and monogenic disease panels. Lastly, other test types include pharmacogenomics, preimplantation genetic diagnosis (PGD), whole exome sequencing (WES), whole genome sequencing (WGS), and mitochondrial DNA testing.

New additions to our 2026 reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.